Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor Lymphocyte Infusion After Nonmyeloablative Hematopoietic Cell Transplantation
NCT00068718Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- May 2003
- Primary completion
- Apr 2013
- Modality
- Cell Therapies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of allogeneic lymphocytes in chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and 3 more, sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Incidence of Grade IV Acute Graft-versus-Host Disease. Started May 2003; status: completed.
02
Drugs
allogeneic lymphocytes
03
Conditions
chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00068718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00068718.